Hospital
UNM Sandoval Regional Medical Center, INC
UNM Sandoval Regional Medical Center, INC was paid $27.38M by Medicaid between Jan 2018 and Dec 2023, across 262 billing codes. Its largest line is 99283, emergency room visit (moderate) — 11% of everything it billed.
33Billing provider infoUNM SANDOVAL REGIONAL MEDICAL CENTER, INC
RIO RANCHO, NM 87144
RIO RANCHO, NM 87144
33aNPI1649556200assigned 10/27/2011
33bProvider typeGeneral Acute Care Hospital
28Total paid$27.38M
24GClaims526,159
24DCodes billed262
24AFirst – last monthJan 2018 – Dec 2023
Compared with peers
Next to other General Acute Care Hospital providers in New Mexico
Rank by total paid#10 of 24
Median peer was paid$20.13M
This provider vs. median1.4×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 103,003 | $4.92M | |
| 2019 | 83,669 | $4.00M | |
| 2020 | 63,273 | $2.91M | |
| 2021 | 77,253 | $3.51M | |
| 2022 | 89,768 | $5.12M | |
| 2023 | 109,193 | $6.92M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 11% | 19,529 | 18,421 | $3.03M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 11% | 37,237 | 33,071 | $2.93M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 9.8% | 12,313 | 11,390 | $2.68M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 5.7% | 5,059 | 4,768 | $1.56M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 5.3% | 4,591 | 4,375 | $1.45M |
| G0378 | Hospital observation service, per hour | 5.0% | 2,826 | 2,435 | $1.36M |
| 70450 | Computed tomography, head or brain; without contrast material | 2.9% | 3,627 | 3,423 | $798K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 2.3% | 9,911 | 8,714 | $625K |
| 80048 | Basic metabolic panel (calcium, ionized) | 1.8% | 29,540 | 23,383 | $504K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.6% | 4,521 | 4,372 | $425K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 1.5% | 3,397 | 3,255 | $411K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.4% | 10,159 | 9,207 | $391K |
250 more codes
| 96375 | Therapeutic injection; each additional sequential IV push | 1.3% | 6,820 | $364K |
| 71275 | Computed tomographic angiography, chest, with contrast material | 1.3% | 927 | $356K |
| 71046 | Radiologic examination, chest; 2 views | 1.3% | 6,351 | $344K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.1% | 878 | $311K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.1% | 6,155 | $306K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.1% | 2,837 | $295K |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 1.0% | 284 | $285K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 882 | $253K |
| 20610 | <1% | 1,768 | $230K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 2,408 | $222K |
| 73562 | <1% | 2,603 | $222K | |
| 80076 | <1% | 14,811 | $215K | |
| 85027 | <1% | 23,091 | $205K | |
| Q3014 | Telehealth originating site facility fee | <1% | 5,159 | $192K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 7,658 | $181K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,465 | $178K |
| 93976 | <1% | 1,358 | $175K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 700 | $174K |
| 71045 | Radiologic examination, chest; single view | <1% | 2,884 | $157K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 900 | $148K |
| 73610 | <1% | 1,429 | $147K | |
| 76830 | Ultrasound, transvaginal | <1% | 1,359 | $145K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 667 | $145K |
| 95811 | <1% | 177 | $128K | |
| 73130 | <1% | 1,723 | $127K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 233 | $126K |
| 73630 | <1% | 1,693 | $124K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 9,946 | $120K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 2,542 | $119K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 3,276 | $112K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 8,318 | $111K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 246 | $108K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 4,642 | $106K |
| 36415 | Collection of venous blood by venipuncture | <1% | 11,365 | $105K |
| 84484 | <1% | 6,931 | $105K | |
| 73030 | <1% | 1,201 | $105K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 2,724 | $104K |
| 84702 | <1% | 4,196 | $103K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 3,993 | $101K |
| 96376 | <1% | 2,978 | $101K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 558 | $99K |
| 83690 | <1% | 10,146 | $95K | |
| C1776 | Joint device (implantable) | <1% | 43 | $94K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,816 | $89K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 680 | $87K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 680 | $86K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 5,653 | $80K |
| 81001 | <1% | 13,213 | $74K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,539 | $73K |
| 83735 | <1% | 7,925 | $72K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 2,696 | $72K |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 893 | $69K |
| 73564 | <1% | 627 | $67K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 877 | $64K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 7,417 | $64K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 784 | $63K |
| 87040 | <1% | 2,068 | $62K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,539 | $61K |
| 83605 | <1% | 4,027 | $60K | |
| 82077 | <1% | 1,579 | $58K | |
| J3490 | Unclassified drugs | <1% | 3,849 | $57K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 427 | $55K |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | <1% | 525 | $55K |
| 73110 | <1% | 730 | $55K | |
| J2704 | Injection, propofol, 10 mg | <1% | 3,508 | $54K |
| 73502 | <1% | 837 | $54K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 4,187 | $52K |
| 94761 | <1% | 2,003 | $51K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 564 | $49K |
| 36000 | <1% | 3,619 | $49K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 1,091 | $46K |
| 93975 | <1% | 282 | $45K | |
| 70498 | <1% | 97 | $45K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 791 | $44K |
| 80061 | Lipid panel | <1% | 2,785 | $44K |
| 51798 | <1% | 908 | $44K | |
| 84100 | <1% | 6,574 | $41K | |
| 49083 | <1% | 160 | $41K | |
| 72100 | <1% | 423 | $41K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 566 | $41K |
| 90837 | Psychotherapy session, about an hour | <1% | 304 | $39K |
| 86850 | <1% | 2,142 | $38K | |
| 97161 | <1% | 1,644 | $38K | |
| 83880 | <1% | 1,219 | $36K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 7,807 | $35K |
| 76000 | <1% | 245 | $33K | |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 40 | $29K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 604 | $29K |
| 76942 | <1% | 220 | $28K | |
| 77080 | <1% | 364 | $28K | |
| 87077 | <1% | 2,278 | $28K | |
| 93971 | <1% | 270 | $27K | |
| 71250 | <1% | 168 | $27K | |
| 80053 | Comprehensive metabolic panel | <1% | 3,190 | $26K |
| 86140 | <1% | 3,883 | $25K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 486 | $25K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 65 | $24K |
| 80143 | <1% | 857 | $24K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 3,346 | $24K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,294 | $23K |
| 73590 | <1% | 316 | $23K | |
| 80179 | <1% | 814 | $23K | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 1,547 | $23K |
| 36561 | <1% | 14 | $22K | |
| 87186 | <1% | 1,807 | $22K | |
| 85610 | <1% | 4,434 | $22K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 2,316 | $21K |
| 84439 | <1% | 1,793 | $21K | |
| 82728 | <1% | 1,279 | $21K | |
| 90715 | <1% | 953 | $20K | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 1,906 | $20K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 5,976 | $20K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 7,969 | $20K |
| 94760 | <1% | 2,455 | $20K | |
| 70496 | <1% | 46 | $19K | |
| 73080 | <1% | 242 | $19K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 56 | $19K |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 1,199 | $18K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,262 | $18K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 301 | $17K |
| 85379 | <1% | 1,133 | $17K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 474 | $17K |
| 82805 | <1% | 182 | $15K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 1,839 | $14K |
| 82607 | <1% | 781 | $14K | |
| 85730 | <1% | 1,823 | $14K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 4,109 | $14K |
| 70486 | <1% | 68 | $13K | |
| C9290 | Injection, bupivacaine liposome, 1 mg | <1% | 39 | $13K |
| 85652 | <1% | 3,461 | $13K | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 1,082 | $12K |
| 88304 | <1% | 353 | $11K | |
| 99152 | <1% | 375 | $11K | |
| 82550 | <1% | 1,343 | $11K | |
| 97165 | <1% | 496 | $11K | |
| 82570 | <1% | 1,674 | $11K | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 845 | $11K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 179 | $11K |
| 83550 | <1% | 1,012 | $10K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 39 | $10K |
| 86900 | <1% | 2,428 | $10K | |
| 86901 | <1% | 2,587 | $10K | |
| 82043 | <1% | 866 | $10K | |
| 73090 | <1% | 117 | $10K | |
| 83970 | <1% | 207 | $10K | |
| 72110 | <1% | 96 | $10K | |
| G0008 | Administration of influenza virus vaccine | <1% | 549 | $9K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 3,303 | $9K |
| 92504 | <1% | 1,051 | $9K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 312 | $9K |
| 86803 | <1% | 365 | $9K | |
| 82746 | <1% | 479 | $9K | |
| 83540 | <1% | 1,085 | $8K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 2,257 | $8K |
| 76770 | <1% | 65 | $8K | |
| 97116 | <1% | 469 | $8K | |
| J2560 | Injection, phenobarbital sodium, up to 120 mg | <1% | 223 | $8K |
| 92557 | <1% | 72 | $7K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 4,713 | $7K |
| 94660 | <1% | 77 | $7K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 96 | $6K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 12 | $6K |
| C1769 | Guide wire | <1% | 253 | $6K |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 432 | $6K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 102 | $6K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 16 | $6K |
| 97113 | <1% | 41 | $6K | |
| 84134 | <1% | 305 | $5K | |
| 62323 | <1% | 12 | $5K | |
| 76536 | <1% | 57 | $5K | |
| 77091 | <1% | 87 | $5K | |
| 82140 | <1% | 254 | $5K | |
| 87632 | <1% | 21 | $5K | |
| 82565 | <1% | 907 | $5K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 731 | $5K |
| J1815 | Injection, insulin, per 5 units | <1% | 335 | $5K |
| 90686 | <1% | 365 | $4K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,522 | $4K |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 319 | $4K |
| 72170 | <1% | 38 | $4K | |
| G0475 | Hiv antigen/antibody, combination assay, screening | <1% | 498 | $4K |
| 86038 | <1% | 242 | $4K | |
| 88342 | <1% | 70 | $4K | |
| 80074 | <1% | 52 | $4K | |
| 81513 | <1% | 26 | $3K | |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 32 | $3K |
| 81002 | <1% | 468 | $3K | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 1,009 | $3K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 102 | $3K |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 155 | $3K |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 457 | $2K |
| 12001 | <1% | 13 | $2K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 32 | $2K |
| C1788 | Port, indwelling (implantable) | <1% | 12 | $2K |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 30 | $2K |
| 87641 | <1% | 82 | $2K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 15 | $2K |
| Q2039 | Influenza virus vaccine, not otherwise specified | <1% | 187 | $2K |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,120 | $2K |
| 84156 | <1% | 440 | $2K | |
| 73560 | <1% | 46 | $2K | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 462 | $2K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 54 | $2K |
| 87481 | <1% | 40 | $2K | |
| 87631 | <1% | 15 | $2K | |
| 76642 | <1% | 13 | $2K | |
| 87205 | <1% | 263 | $1K | |
| 86780 | <1% | 63 | $1K | |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 256 | $1K |
| 74018 | <1% | 16 | $1K | |
| 92567 | <1% | 27 | $1K | |
| 87340 | <1% | 64 | $1K | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 148 | $985.56 |
| G0145 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision | <1% | 32 | $955.61 |
| 84460 | <1% | 150 | $861.61 | |
| 84450 | <1% | 150 | $838.88 | |
| 76937 | <1% | 12 | $820.15 | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 12 | $785.98 |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 73 | $768.18 |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | <1% | 31 | $695.27 |
| 87650 | <1% | 16 | $607.88 | |
| Q0091 | Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | <1% | 48 | $606.65 |
| 86480 | <1% | 14 | $590.76 | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 31 | $523.34 |
| 77001 | <1% | 14 | $520.34 | |
| 87338 | <1% | 27 | $487.45 | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 127 | $467.37 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 145 | $382.51 |
| 86225 | <1% | 24 | $379.63 | |
| 87210 | <1% | 52 | $367.70 | |
| 99153 | Mod sedat endo service >5yrs | <1% | 27 | $359.15 |
| 86160 | <1% | 13 | $346.30 | |
| 97164 | <1% | 15 | $344.86 | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 24 | $344.74 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 39 | $334.22 |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 14 | $333.41 |
| 86704 | <1% | 24 | $314.01 | |
| Q9965 | Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml | <1% | 54 | $257.65 |
| J2274 | Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg | <1% | 37 | $254.94 |
| 87075 | <1% | 21 | $228.24 | |
| 87081 | <1% | 24 | $227.37 | |
| 81025 | <1% | 13 | $168.68 | |
| 86430 | <1% | 14 | $158.38 | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 55 | $153.42 |
| 85014 | <1% | 56 | $152.28 | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 70 | $133.65 |
| 84132 | <1% | 31 | $114.01 | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 26 | $56.16 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 27 | $12.82 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 1,490 | $0.10 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSILVA-STEELE, JAMIE (CEO)